Pharmaceutical marketing budgets are going through a period of readjustment as companies explore and exploit a myriad of different digital channels to deliver content to, and engage with, t
Given the recent rise in digital engagement and the drastic increase in digital content, it’s now essential that pharmaceutical companies have a comprehensive content strategy.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh